EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
JAN 2023
TABLES
202
PAGES
264
EDITION
18
PRICE
USD 5600
CODE
MCP-6525
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
What`s New for 2023?
»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
»Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
»Online interactive peer-to-peer collaborative bespoke updates
»Access to our digital archives and MarketGlass Research Platform
»Complimentary updates for one year
Looking Ahead to 2023
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Sepsis Therapeutics Market to Reach $433.2 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Sepsis Therapeutics estimated at US$26.5 Billion in the year 2022, is projected to reach a revised size of US$433.2 Billion by 2030, growing at a CAGR of 41.8% over the period 2022-2030.
The U.S. Market is Estimated at $9.1 Billion, While China is Forecast to Grow at 38.1% CAGR
The Sepsis Therapeutics market in the U.S. is estimated at US$9.1 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$59.1 Billion by the year 2030 trailing a CAGR of 38.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 36% and 34.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 31.9% CAGR.
SELECT PLAYERS
Adrenomed AG; AM-Pharma B.V.; Aridis Pharmaceuticals Inc.; Asahi Kasei Pharma America; Astellas Pharma Inc.; Endacea Inc.; InflaRx GmbH; La Jolla Pharmaceutical Company; Opsonix, Inc.; T2 Biosystems Inc.; TaiRx Inc.
SEGMENTS
» Segment (Sepsis Therapeutics)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Sepsis - A Prelude |
Recent Market Activity |
New Treatment Protocols and New Definitions - Every Minute Counts!! |
Aging Population: A Key Growth Driver for Sepsis Therapeutics |
Antibiotics and Vasopressors - The Current Standard of Care |
Current Categories of Antibacterial Agents for First-line Sepsis Treatment |
Current Anti-bacterial Drugs used in Sepsis |
Current Antifungals used for Sepsis |
Current Antivirals used for Sepsis |
GIAPREZA - The Only FDA Approved Branded Drug for Sepsis Treatment |
Argipressin Gains Approval for Septic Shock in 26 EU countries |
Current & Future Analysis |
Growth Drivers in a Nutshell |
Market Restraints |
Sepsis Therapeutics – Global Key Competitors Percentage Market Share in 2022 (E) |
Impact of Covid-19 and a Looming Global Recession |
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
2. FOCUS ON SELECT PLAYERS |
Adrenomed AG (Germany) |
AM-Pharma B.V. (Netherlands) |
AMOMED Pharma GmbH (Austria) |
Asahi Kasei Pharma America (USA) |
Endacea, Inc. (USA) |
InflaRx N.V. (Germany) |
La Jolla Pharmaceutical Company (USA) |
TaiRx, Inc. (USA) |
3. MARKET TRENDS & DRIVERS |
A Market Characterized by High Unmet Medical Needs |
Research Activity Enables Increased Awareness of Disease Pathogenesis |
Select Sepsis Therapeutics under Phase IV Clinical Trials: As of 2018 |
Select Sepsis Therapeutics under Phase III Clinical Trials: 2018 |
Novel Immune-Specific Modes of Action under Focus |
Emphasizing on Endothelial Cell Function |
HMGB1 - A Potential Target for Future Therapies |
Nanoparticle Systems Demonstrate Potential for Use in Septic Shock Management |
Researchers Employ IL-7 to Increase CD4 and CD8 Immune Cells in Patients |
Hydrocortisone Displays Potential in Septic Shock Treatment |
Reduced Levels of Vitamin C Characterize Sepsis Patients |
Treatment with Hydrocortisone and Vitamin C Demonstrates Positive Impact on Mortality Rate |
Intravenous Vitamins + Hydrocortisone Therapy Causes Waves in the Market |
Researchers Develop ss-Sepsis-3 Protocol for Evaluation of Sepsis in Animal Models |
World Sepsis Day Aims to Result in Improvement in Sepsis Management |
NSAIDs Demonstrate Potential to Treat Sepsis |
4. GLOBAL MARKET PERSPECTIVE |
World Sepsis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027 |
World Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2021 & 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
USA Recent Past, Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
CANADA |
Canada Recent Past, Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
JAPAN |
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
Japan Recent Past, Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
CHINA |
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
China Recent Past, Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
EUROPE |
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
Europe 7-Year Perspective for Sepsis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2021 & 2027 |
FRANCE |
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
France Recent Past, Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
GERMANY |
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
Germany Recent Past, Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
ITALY |
Italy Recent Past, Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UNITED KINGDOM |
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
UK Recent Past, Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
ASIA-PACIFIC |
Sepsis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
REST OF WORLD |
Rest of World Recent Past, Current & Future Analysis for Sepsis Therapeutics by Segment - Sepsis Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com